{
  "source": "PA-Med-Nec-Altuviiio.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2300-3\nProgram Prior Authorization/Medical Necessity\nMedication Altuviiio® [antihemophilic factor (recombinant), Fc-VWF-XTEN\nfusion protein-ehtl]\nP&T Approval Date 4/2023, 4/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nAltuviiio® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl)] is a\nrecombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with\nhemophilia A (congenital factor VIII deficiency) for:\nRoutine prophylaxis to reduce the frequency of bleeding episodes\no\nOn-demand treatment and control of bleeding episodes\no\nPerioperative management of bleeding\no\nAltuviiio is not indicated for the treatment of von Willebrand disease.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Altuviiio will be approved based on all of the following criteria:\na. Diagnosis of hemophilia A\n-AND-\nb. Altuviiio is being prescribed for one of the following:\n(1) Treatment of bleeding episodes\n(2) Prevention of bleeding in surgical interventions or invasive procedures (e.g.,\nsurgical prophylaxis)\n(3) Prevention of bleeding episodes (i.e., routine prophylaxis)\n-AND-\nc. Patient is not a suitable candidate for treatment with shorter acting half-life Factor\nVIII (recombinant) products [e.g., Advate, Kogenate FS, Kovaltry, Novoeight,\nNuwiq, or Recombinate] as attested by the prescribing physician\n-AND-\nd. Both of the following:\n(1) Dose does not exceed 50 IU/kg\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Patient is infusing no more frequently than every 7 days\nAuthorization of therapy will be issued for 12 months.\nB. Reauthorization\n1. Altuviiio will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Altuviiio therapy\n-AND-\nb. Both of the following:\n(1) Dose does not exceed 50 IU/kg\n-AND-\n(2) Patient is infusing no more frequently than every 7 days\nAuthorization of therapy will be issued for 12 months.\na ",
    "o therapy\n-AND-\nb. Both of the following:\n(1) Dose does not exceed 50 IU/kg\n-AND-\n(2) Patient is infusing no more frequently than every 7 days\nAuthorization of therapy will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Altuviiio™ [package insert]. Waltham, MA: Bioverativ Therapeutics Inc., September 2024.\n2. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia\nand Selected Disorders of the Coagulation System. MASAC Document #290, October 2,\n2024.\nProgram Prior Authorization/Medical Necessity - Altuviiio\nChange Control\n4/2023 New program.\n4/2024 Annual review. No changes to coverage criteria. Updated reference.\n4/2025 Annual review. No changes to coverage criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}